C-88QKRefoxy Pharma
FOXO3 modulation, cellular resilience, age-related disease therapeutics
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-88QK
C-88QKC-88QKFOXO3 modulation, cellular resilience, age-related disease therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Refoxy Pharma FOXO3 modulation, cellular resilience, age-related disease therapeutics
Refoxy develops next-generation medicines to treat age-related diseases and extend the number of years people can live in good health. Its work targets FOXO3, described on the site as a master regulator of cellular resilience. The company focuses on conditions including Idiopathic Pulmonary Fibrosis, fibrotic diseases, and cardiovascular diseases.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Refoxy Pharma — Far from goals · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic